Izvorni znanstveni članak
https://doi.org/10.3325/cmj.2021.62.504
SIRT1 and Klotho expression in the heart and kidneys of rats with acute and chronic renovascular hypertension
Mahboobeh Yeganeh Hajahmadi
; Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran
Hamid Najafipour
; Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran
Farzaneh Rostamzadeh
; Endocrinology and Metabolism Research Center, Kerman University of Medical Sciences, Kerman, Iran
Yaser Masoumi-Ardakan
; Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran
Sažetak
Aim To evaluate Klotho and SIRT1 expression in the heart
and kidneys of rats with acute and chronic renovascular
hypertension.
Methods Four and sixteen weeks after the induction of
renovascular hypertension by clipping the left renal artery,
systemic blood pressure, serum angiotensin II level, and
the expression of Klotho and SIRT1 proteins and oxidative
stress indices in the heart and kidneys were assessed.
Results SIRT1 level was significantly reduced in the ischemic (left) kidney in acute and chronic phases of hypertension. In the heart, it decreased in the acute phase, but
increased in the chronic phase. Klotho levels in the heart
and kidneys did not change significantly in either hypertension phase. Superoxide dismutase (SOD) activity in the
heart significantly decreased, and SOD, total antioxidant
capacity, and malondialdehyde in the ischemic kidney significantly increased during the development of hypertension. Serum angiotensin II level significantly increased in
the acute phase of hypertension.
Conclusion Development of renovascular hypertension
was associated with a reduction of SIRT1 expression in
the heart and ischemic kidney. As angiotensin II and SIRT1
counteract each other’s expression, a SIRT1 reduction in
the heart and kidney, along with the influence of systemic/
local angiotensin II, seems to be partly responsible for hypertension development. A combination of SIRT1 agonists
and angiotensin II antagonists may be considered for use
in the treatment of renovascular hypertension.
Ključne riječi
Hrčak ID:
278796
URI
Datum izdavanja:
21.10.2021.
Posjeta: 609 *